NASDAQ:VSAR - Versartis Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.19 0.00 (0.00 %) (As of 05/20/2019 12:22 PM ET)Previous Close$1.19Today's Range$1.19 - $1.1952-Week Range$1.14 - $2.76VolumeN/AAverage Volume479,436 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. It is developing somavaratan, a long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The company was founded in 2008 and is headquartered in Menlo Park, California. Receive VSAR News and Ratings via Email Sign-up to receive the latest news and ratings for VSAR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VSAR Previous Symbol CUSIPN/A CIK1513818 Webwww.versartis.com Phone650-963-8580Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableOptionable Versartis (NASDAQ:VSAR) Frequently Asked Questions What is Versartis' stock symbol? Versartis trades on the NASDAQ under the ticker symbol "VSAR." How were Versartis' earnings last quarter? Versartis Inc (NASDAQ:VSAR) posted its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.69. View Versartis' Earnings History. Has Versartis been receiving favorable news coverage? Media headlines about VSAR stock have been trending somewhat negative this week, InfoTrie reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Versartis earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of Versartis' key competitors? Some companies that are related to Versartis include Advanced Accelerator Application (AAAP), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO), Egalet (EGLT), Eleven Biotherapeutics (EBIO) and Epirus Biopharmaceuticals (EPRSQ). What other stocks do shareholders of Versartis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Versartis investors own include Energous (WATT), Progenics Pharmaceuticals (PGNX), ZIOPHARM Oncology (ZIOP), Genocea Biosciences (GNCA), Novavax (NVAX), Bausch Health Companies (BHC), Fate Therapeutics (FATE), SCYNEXIS (SCYX), Spectrum Pharmaceuticals (SPPI) and Zynerba Pharmaceuticals (ZYNE). Who are Versartis' key executives? Versartis' management team includes the folowing people: Mr. Jay P. Shepard, Pres, CEO & Director (Age 60)Ms. Tracy M. Woody, Chief Commercial Officer (Age 48)Dr. Jeffrey L. Cleland, Co-Founder (Age 53)Dr. Joshua Silverman Ph.D., Co-FounderMr. Kevin Haas, VP of Fin. (Age 53) How do I buy shares of Versartis? Shares of VSAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Versartis' stock price today? One share of VSAR stock can currently be purchased for approximately $1.19. What is Versartis' official website? The official website for Versartis is http://www.versartis.com. How can I contact Versartis? Versartis' mailing address is 1020 Marsh Rd, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-963-8580 or via email at [email protected] MarketBeat Community Rating for Versartis (NASDAQ VSAR)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 280 (Vote Outperform)Underperform Votes: 247 (Vote Underperform)Total Votes: 527MarketBeat's community ratings are surveys of what our community members think about Versartis and other stocks. Vote "Outperform" if you believe VSAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSAR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: Green Investing Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.